Emphysema
A progressive, permanent destruction of the air sacs in the lungs, most often a consequence of years of smoking — but in a minority of patients, especially younger and non-smoking ones, it has a purely genetic cause that surprisingly few people know about.
Number of studies
2
Safety
Requires caution
Time to effects
Quitting smoking doesn't reverse already-occurred tissue destruction, but significantly slows the further rate of FEV1 decline already within the first year after sustained cessation; pulmonary rehabilitation typically brings measurable improvement in exercise tolerance after 6–12 weeks of a regular program, and the effect of bronchodilators on breathlessness can be felt within days to weeks of starting treatment.
Who it's for
Table of contents
TL;DR
A progressive, permanent destruction of the air sacs in the lungs, most often a consequence of years of smoking — but in a minority of patients, especially younger and non-smoking ones, it has a purely genetic cause that surprisingly few people know about.
- →Understanding alpha-1 antitrypsin's role allows recognition of a rarer, genetic cause of emphysema in young or non-smoking patients, opening the door to specific diagnosis and replacement therapy
- →Early spirometry in long-term smokers with breathlessness enables diagnosis before serious functional limitation sets in
- →Quitting smoking, even at a moderately advanced disease stage, significantly slows further lung function decline
| Condition type | Chronic, progressive destruction of lung alveoli — one of the two main forms of COPD |
|---|---|
| Level of evidence | Strong — well-described pathophysiology, diagnosis, and symptomatic treatment |
| Dominant risk factor | Long-term tobacco smoking (vast majority of cases) |
| Rarer genetic cause | Alpha-1 antitrypsin deficiency (SERPINA1 gene mutations) — earlier disease onset |
| Diagnosis | Spirometry (poorly reversible obstruction), chest HRCT, alpha-1 antitrypsin level |
| Status | Chronic, structurally irreversible disease — treatment focuses on slowing progression and easing symptoms |
Understand
Overview
Emphysema is a chronic, progressive, and structurally irreversible lung disease in which the walls of the alveoli and the surrounding fibro-elastic septa are permanently destroyed, leading to abnormal, permanent enlargement of the airspaces distal to the terminal bronchioles. In practice, this means lung tissue loses its natural, sponge-like structure with an enormous gas-exchange surface, replaced by fewer, much larger, less elastic air spaces — which drastically reduces the surface available for oxygen and carbon dioxide exchange and weakens the natural "springiness" of the lungs needed for an effective exhale.
Emphysema is one of the two main, often co-occurring forms of chronic obstructive pulmonary disease (COPD) — the other is chronic bronchitis. In most COPD patients, both forms overlap to varying degrees, and pure, isolated emphysema without a chronic bronchitis component is relatively rare. This distinction matters clinically: emphysema dominates the picture of tissue destruction and loss of elasticity, while chronic bronchitis dominates the picture of chronic productive cough and airway narrowing from mucous gland hypertrophy — in practice, most patients present a mixed picture of both processes.
By far the dominant risk factor for emphysema worldwide is long-term tobacco smoking — it accounts for the vast majority of diagnosed cases, with risk rising in proportion to the number of years smoked and the number of cigarettes smoked (so-called pack-years). Other, rarer risk factors include long-term exposure to air pollution, industrial dust, and biomass-burning smoke (particularly relevant in developing countries, where cooking over open fires in poorly ventilated spaces is a common cause of emphysema in non-smokers) and chronic, poorly controlled asthma over many years.
There is, however, a second, much rarer cause that's often left out of discussions of emphysema and is purely genetic: alpha-1 antitrypsin deficiency (AATD). This is an autosomal-inherited disorder in which mutations in the SERPINA1 gene lead to insufficient production or an abnormal structure of alpha-1 antitrypsin — a protein that protects lung tissue from the proteolytic enzymes released by neutrophils during normal inflammatory processes. In people with severe deficiency (the ZZ genotype), emphysema develops significantly earlier than in the typical, smoking-related form of the disease — often already in the fourth or fifth decade of life — and in smokers who carry this mutation, the disease progresses even faster and more aggressively than in those without this genetic burden. Clinically important, AATD can also cause emphysema in people who have never smoked — a clinical scenario that should always prompt consideration of testing for this deficiency, especially with early-onset disease or a family history.
The clinical picture of emphysema usually develops very slowly, over many years, and typically includes progressive exertional breathlessness (initially noticeable only with heavy exertion, eventually limiting even everyday activities), chronic cough (though less pronounced than in dominant chronic bronchitis), reduced exercise tolerance, and, in advanced stages, the characteristic "barrel chest" appearance resulting from chronic lung hyperinflation caused by trapped air from loss of tissue elasticity.
Diagnosis relies mainly on spirometry, which confirms airway obstruction (reduced FEV1/FVC ratio) that doesn't fully reverse after a bronchodilator, unlike asthma — this test, its performance, and interpretation are covered in detail in our spirometry entry. High-resolution chest CT (HRCT) shows the characteristic low-attenuation areas (destroyed lung tissue) and allows assessment of the extent and distribution of changes, which matters when considering certain lung-volume-reduction surgeries in selected patients.
Who might genuinely benefit from this knowledge? Primarily current and former long-term smokers with progressive breathlessness, for whom spirometry testing is worth considering before symptoms become seriously limiting. Equally important is this knowledge for people diagnosed with emphysema at a young age, non-smoking emphysema patients, and people with a family history of early-onset COPD — in these groups, testing alpha-1 antitrypsin levels is a diagnostic step that can genuinely change further management, including the possibility of cause-specific replacement therapy rather than just symptomatic treatment.
Mechanism of action
Physiologically healthy lung tissue maintains a delicate balance between proteolytic enzymes (chiefly neutrophil elastase, released by neutrophils as part of the normal immune response to minor, everyday irritants inhaled with air) and antiprotease proteins, the most important being alpha-1 antitrypsin, produced mainly in the liver and transported to the lungs, where it neutralizes excess elastase, protecting the elastin fibers that build alveolar walls. Emphysema develops when this balance is permanently disrupted in favor of tissue damage — whether through excess elastase production (as in the chronic inflammatory state caused by tobacco smoke) or insufficient functional alpha-1 antitrypsin (as in AATD).
Tobacco smoke damages lung tissue in multiple stages: it irritates the airways and alveoli, triggering chronic, unrelenting infiltration by neutrophils and macrophages, which release large amounts of elastase and other proteolytic enzymes as part of a chronic inflammatory reaction. At the same time, substances in tobacco smoke directly inactivate and impair the function of circulating alpha-1 antitrypsin by oxidizing key methionine residues in its structure, further worsening an already unfavorable protease–antiprotease balance. Repeated over decades, these processes lead to progressive, irreversible destruction of alveolar septa and loss of elastin — the protein responsible for the natural "springiness" of the lungs that drives passive exhalation in healthy lungs.
In alpha-1 antitrypsin deficiency, the mechanism is analogous in its consequences but reversed in its primary cause — it's not elastase overproduction, but insufficient antiprotease protection from the outset that allows neutrophil elastase to destroy lung tissue even at normal, physiological exposure to minor airborne irritants that wouldn't cause any lasting damage in a person with normal alpha-1 antitrypsin levels. SERPINA1 gene mutations (most often the Z and S variants) cause the alpha-1 antitrypsin protein to misfold, so a large portion gets trapped and accumulates in liver hepatocytes (which in some patients additionally leads to liver disease) instead of being properly secreted into the blood and transported to the lungs — in people with the ZZ genotype, circulating protein levels are typically below 15–20% of normal, which is clearly insufficient to compensate for even moderate exposure to irritants.
At the tissue level, loss of elastin and permanent enlargement of airspaces reduces the total gas-exchange surface (impairing oxygen diffusion into the blood, measured by the DLCO parameter) and, equally clinically important, reduces the elastic "recoil" force needed to drive passive exhalation — which is why patients with emphysema have a particular difficulty with effective exhalation and develop so-called dynamic hyperinflation (air trapped in the lungs that hasn't been exhaled before the next breath), the main cause of the progressive exertional breathlessness typical of this disease.
Protease–antiprotease imbalance
Excess neutrophil elastase (tobacco smoke) or deficient protective alpha-1 antitrypsin (AATD) shifts the balance against lung tissue protection.
Chronic inflammatory infiltration
Tobacco smoke and other irritants trigger persistent infiltration by neutrophils and macrophages releasing proteolytic enzymes.
Destruction of elastin and alveolar walls
Uncontrolled protease activity destroys elastin fibers and alveolar septa, causing permanent enlargement of airspaces.
Loss of elastic recoil and dynamic hyperinflation
Damaged tissue no longer effectively drives passive exhalation, air gets trapped in the lungs, manifesting as progressive exertional breathlessness.
Evidence: strong — based on 2 studies in this database.
Benefits
Common myths
MythEmphysema only affects people who smoked or still smoke.
FactAlthough smoking is the dominant risk factor, the rarer, genetically determined form of the disease (alpha-1 antitrypsin deficiency) can develop even in people who never smoked — this scenario is real, though much rarer, and requires separate diagnostic workup.
MythIf the lungs are already damaged, quitting smoking doesn't make much sense anymore.
FactThe Lung Health Study showed a significantly smaller further decline in lung function in people who achieved sustained smoking cessation, regardless of the disease stage at the time of quitting — stopping smoking remains the most important intervention at every stage.
MythEmphysema is diagnosed mainly from a chest X-ray.
FactThe basic test confirming obstruction is spirometry; a standard chest X-ray can be normal even with significant emphysema, while high-resolution CT provides a far more accurate assessment of the extent of changes.
MythBronchodilators treat the underlying cause of emphysema.
FactThey ease breathlessness and improve exercise tolerance by relaxing bronchial smooth muscle, but they don't reverse or halt the destruction of alveolar tissue itself, which is structurally irreversible.
Forms & variants
Emphysema comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Smoking-related emphysema
By far the most common form, usually with predominant involvement of the upper lung zones, developing after decades of smoking.
Best for: Smoking cessation as the intervention with the greatest impact on further course
Emphysema from alpha-1 antitrypsin deficiency (AATD)
A rarer, genetically determined form, typically affecting the lower lung zones, with earlier disease onset, sometimes in non-smokers.
Best for: Young, non-smoking patients, or those with a family history of early COPD — an indication for alpha-1 antitrypsin level testing
Emphysema linked to air pollution and biomass smoke
Particularly significant in developing countries, where cooking over open fires in poorly ventilated spaces is a common cause of disease in non-smokers, mainly women.
Best for: Populations with significant environmental exposure independent of tobacco smoking
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
COPD is a broader term covering two main, usually co-occurring forms: emphysema (alveolar destruction) and chronic bronchitis (chronic productive cough and airway narrowing). Most patients present a mixed clinical picture with varying contributions from each component.
No — destruction of alveolar walls and loss of elastin are structurally irreversible. Treatment focuses on slowing further progression (chiefly by quitting smoking) and easing symptoms and improving quality of life, not reversing already-occurred changes.
Primarily when emphysema or COPD is diagnosed before age 45, in non-smokers with emphysema, with an atypical (lower-lobe) distribution of changes on CT, and with a family history of early-onset COPD or unexplained liver disease.
Yes — studies show a significantly smaller further decline in lung function in people who achieve sustained smoking cessation, regardless of the disease stage at the time of quitting. It remains the most important, fully modifiable intervention at every stage of the disease.
Spirometry confirms airway obstruction that's poorly reversible with a bronchodilator, and high-resolution chest CT (HRCT) shows the characteristic destroyed, emphysematous lung tissue areas and allows assessment of their extent and distribution.
What actually helps
Complete smoking cessation
Strong evidenceThe single most important, fully modifiable intervention — the Lung Health Study showed a significantly smaller decline in FEV1 in groups with intensive smoking-cessation intervention than in the usual-care group.
Pulmonary rehabilitation
Strong evidenceA structured program of physical exercise, education, and breathing training that improves exercise tolerance, quality of life, and reduces exacerbation-related hospitalizations.
Bronchodilators (LABA/LAMA)
Strong evidenceLong-acting beta-2 agonists and anticholinergics ease breathlessness and improve exercise tolerance, though they don't halt the progression of tissue destruction.
Influenza and pneumococcal vaccination
Strong evidenceReduces the risk of exacerbations triggered by respiratory infection, the main cause of hospitalization in emphysema patients.
Chronic home oxygen therapy
Strong evidenceIn patients with documented chronic hypoxemia, extends survival — one of the few COPD interventions with a documented effect on mortality.
Alpha-1 antitrypsin replacement therapy
Moderate evidenceIntravenous administration of purified protein in patients with confirmed severe deficiency (AATD) and documented emphysema — slows the rate of lung tissue loss in this specific patient subgroup.
Surgical lung-volume reduction or bullectomy
Moderate evidenceProcedures reserved for selected patients with heterogeneously distributed emphysema and large emphysematous bullae, improving breathing mechanics in an appropriately selected group.
What to combine with
Good combinations
Spirometry — Spirometry is the basic test confirming the airway obstruction typical of emphysema and COPD — a full description of the test, how it's performed, and interpretation is in this entry.
Safety
Side effects & contraindications
Possible side effects
Progressive exertional breathlessness that eventually limits even basic daily activities (washing, walking on level ground)
Increased risk of exacerbations with accompanying respiratory infection, sometimes requiring hospitalization
Chronic hypoxemia in advanced stages leading to pulmonary hypertension and right-heart strain (cor pulmonale)
Unintentional weight loss and muscle wasting in advanced disease due to the increased energy cost of breathing itself
In people with alpha-1 antitrypsin deficiency — additional risk of liver disease (cirrhosis) from accumulation of misfolded protein in hepatocytes
Increased risk of pneumothorax from rupture of emphysematous bullae in advanced disease
Contraindications
No significant contraindications at typical doses.
Interactions
Continuing to smoke after diagnosis — the most important, fully modifiable factor accelerating further lung function loss
Occupational exposure to dust, fumes, and airway irritants worsens disease progression independent of smoking
Respiratory infections (viral and bacterial) are the most common cause of exacerbations and accelerate long-term lung function decline
Smoking in carriers of SERPINA1 gene mutations (even heterozygous carriers) significantly accelerates disease development compared with non-smoking carriers of the same mutation
Air pollution and biomass-burning smoke in poorly ventilated spaces are a significant risk factor, especially in non-smokers
Is it worth taking?
Who it's for
- Current and former long-term smokers with progressive exertional breathlessness or chronic cough
- People diagnosed with emphysema at a young age (before 45) or non-smoking emphysema patients
- People with a family history of early-onset COPD or emphysema
- People occupationally exposed to industrial dust, fumes, or other airway irritants
Not for
- No significant contraindications at typical doses.
Evidence
Worth knowing
Emphysema is one of two main, usually co-occurring forms of COPD, alongside chronic bronchitis.
Alpha-1 antitrypsin deficiency (SERPINA1 gene mutations) is a rare but fully genetic cause of emphysema, sometimes in non-smokers.
In people with the ZZ genotype of alpha-1 antitrypsin deficiency, circulating protein levels are typically below 15–20% of normal.
In the Lung Health Study, sustained smoking cessation significantly slowed the rate of FEV1 decline already in the first year of observation.
Chronic home oxygen therapy is one of the few interventions in advanced COPD with a documented effect on extending survival.
Studies
Both intervention arms (intensive smoking-cessation intervention) showed a significantly smaller decline in FEV1 over five years than the usual-care group — most of this difference came from improved lung function already in the first year among those who achieved sustained smoking cessation.
Anthonisen NR et al., Lung Health Study, JAMA, 1994
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study
Strong evidenceAnthonisen NR, Connett JE, Kiley JP, et al. · JAMA · 1994
A trial of 5,887 smokers with early spirometric signs of COPD across 10 centers in the US and Canada. Groups receiving intensive smoking-cessation intervention had significantly smaller FEV1 decline after 5 years (184 mL and 209 mL) than the usual-care group (267 mL) — most of the difference came from improved lung function in the first year among those who achieved sustained cessation.
View studyAlpha1-antitrypsin deficiency. 2: genetic aspects of alpha1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk
Strong evidenceDeMeo DL, Silverman EK · Thorax · 2004
A review of the genetic basis of alpha-1 antitrypsin deficiency, including the role of SERPINA1 gene mutations (Z and S variants) in earlier-onset emphysema, and factors modifying risk in mutation carriers, including the key role of tobacco smoking in accelerating progression.
View studySources & bibliography
- Anthonisen et al. 1994 — JAMA, Lung Health Study
- DeMeo, Silverman 2004 — Thorax
- GOLD — Global Strategy for Diagnosis, Management and Prevention of COPD
The PubMed identifiers in this knowledge base were checked against NCBI records (October 2026). If you spot an error in a source, please let us know via the contact form.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
297 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
227 publications on this site
Related entries
4.6Spirometry
Spirometry is the basic, non-invasive lung function test that measures the volume and speed of airflow during breathing — the foundation for diagnosing asthma, COPD, and other respiratory conditions and for tracking their course over time.
4.7Hypertension
The 'silent killer' — it runs symptom-free for years, yet it's one of the strongest, and largely modifiable, risk factors for stroke and heart attack in the world.
4.7Type 2 Diabetes
A chronic metabolic disease in which the body loses its ability to properly regulate blood glucose — and one of the few chronic diseases where a large randomized trial showed that lifestyle change alone can outperform a drug.
4.7Osteoporosis
A progressive decline in bone mineral density, especially pronounced in postmenopausal women — a network meta-analysis of 74 studies shows exactly which forms of physical activity genuinely slow this process down.
4.7Migraine
A chronic neurological disease causing recurring, severe headache attacks — usually one-sided, pulsating, and worsened by physical activity — which can come with nausea, sensitivity to light and sound, and aura. It's not 'just a bad headache' but a distinct disease with its own neurobiological mechanism, affecting more than a billion people worldwide.
4.7Kidney Stones
Mineral deposits forming in the urinary tract when the concentration of lithogenic substances in urine exceeds its solubility threshold — a classic RCT by Borghi showed that simply increasing fluid intake by nearly half cuts recurrence risk.
Related articles
PoradnikiAdult Asthma: Symptoms, Triggers, and What Good Treatment Actually Looks Like
Asthma in adults is often mistaken for a chronic cough, a lingering allergy, or simply "being out of shape" — and even among people who already know they have it, many are still managed the way the disease was treated a decade ago, on the assumption that a rescue inhaler is enough. The latest Global Initiative for Asthma (GINA) guidance changed that approach fairly dramatically. We explain how inhaler types actually differ, why relying on a SABA "whenever needed" is now considered a mistake, and how to recognize when asthma isn't actually under control.
September 16, 2026
PoradnikiLong COVID: Symptoms and Treatment — What Do We Actually Know?
Several years after the peak of the pandemic, long COVID (the persistent aftereffects of COVID-19) still affects a meaningful share of people who've had the infection — from chronic fatigue, through "brain fog," to breathlessness lasting for months. Despite hundreds of identified symptoms, there's still no single approved drug targeted at this condition. We explain the official definition, the most common symptoms according to large analyses, and what currently actually has evidence support in management, and what remains at the research stage.
September 21, 2026
PoradnikiPulmonary Rehabilitation and COPD — What Does the Cochrane Review Show?
Chronic obstructive pulmonary disease (COPD) traps patients in a vicious cycle: breathlessness on exertion discourages movement, avoiding movement deepens deconditioning, and deconditioning worsens breathlessness at ever-lower levels of effort. Pulmonary rehabilitation — a structured exercise program combined with education, not just "breathing exercises" — is one of the few interventions that genuinely breaks this mechanism. The largest Cochrane review on the topic covered 65 randomized trials and nearly 3,800 participants — we look at exactly what it found.
August 27, 2026
PoradnikiN-Acetylcysteine (NAC) and COPD Exacerbations: What Does a Meta-Analysis of 13 Trials Show?
Exacerbations of chronic obstructive pulmonary disease (COPD) are the leading cause of hospitalization and worsened prognosis in patients with the disease. N-acetylcysteine (NAC), best known as a mucolytic, has a meta-analysis of 13 trials in over 4,000 patients behind it, showing a significant, dose-dependent reduction in exacerbation frequency. We look at what dose actually works, and for whom.
September 2, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.